This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Stemline Therapeutics, Inc. (STML) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of STML stock.
Pharmacyclics, Inc.’s (PCYC) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
This is a strong week for Acorda Therapeutics, Inc. (ACOR). The company’s rating climbs to B from the previous week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc. (NWBO) improves from a C to a B rating this week. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
MediciNova, Inc. (MNOV) is seeing ratings go up from a B last week to an A this week. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
BioMarin Pharmaceutical (BMRN) shows solid improvement this week. The company’s rating rises from a C to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) earns a B this week, jumping up from last week’s grade of C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
The rating of Ambit Biosciences Corp. (AMBI) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
This week, Intrexon Corporation’s (XON) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of XON stock.
This week, ADMA Biologics, Inc. (ADMA) pushes up from a B to an A rating. For more information, get Portfolio Grader’s complete analysis of ADMA stock.
Amgen (AMGN) boosts its rating from a B to an A this week. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
